Perrigo Company PLC logo

Perrigo Company PLC(PRGO)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 71 days
PROFIT SINCE LAST BUY
+32.14% ▲
LAST CLOSE
$16.24
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for PRGO

11/13/2026: PRGO (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Perrigo Company PLC is a major player in the consumer self-care market, specializing in store-brand over-the-counter medications and wellness products. The company's strengths lie in its deep-rooted retail partnerships and extensive manufacturing scale, which allow it to provide high-quality, cost-effective health solutions. Its primary growth story revolves around consolidating its position in international markets and leveraging the increasing consumer shift toward affordable health alternatives. However, Perrigo faces risks related to intense competition from national health brands and the complexities of integrating past acquisitions. It may suit dividend-seeking value investors, while shareholders should monitor its progress in streamlining margins and reducing debt.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitGrowth is largely dependent on successful M&A and brand expansion rather than rapid organic innovation.
Momentum investorMixed fitMomentum may be inconsistent; investors should monitor for signs of a sustained breakout in organic growth.
Value investorStrong fitPerrigo often trades at valuation multiples that may appeal to investors looking for stability in the consumer health sector.
Dividend investorStrong fitConsistent dividend payouts make it an attractive option for income-focused portfolios.
Low-risk investorMixed fitRegulatory and integration risks add a layer of complexity that may not suit the most conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highThe stock can be sensitive to quarterly earnings reports and changes in market sentiment regarding consumer spending.
Valuation riskMediumWhile often priced reasonably, valuation is tied to the company's ability to maintain earnings stability.
Competition risk (Generic & Brand competition)HighPerrigo faces constant margin pressure from competitors and national brand manufacturers.
Business qualityMediumThe franchise is solid but has faced challenges in executing a coherent long-term strategy across regions.
Dividend incomeMediumDividends are reliable but not typically characterized by high-growth characteristics.
Execution riskMedium / highSuccessful integration of large acquisitions remains the primary determinant of long-term value creation.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.25B USD
Price to earnings Ratio -
1Y Target Price 18
Price to earnings Ratio -
1Y Target Price 18
Volume (30-day avg) 2.4M shares
Beta 0.69
52 Weeks Range 8.81 - 17.02
Updated Date 11/14/2026
52 Weeks Range 8.81 - 17.02
Updated Date 11/14/2026
Dividends yield (FY) 7.17%
Basic EPS (TTM) -12.47

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -43.65%
Avg. Invested days 34
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
PRGO receives a 3-star rating based on the available scored pillars. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
PRGO has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-729.7%), soft cash generation (FCF margin 3.4%), slightly negative revenue growth (-2.8%).

Financial Health Rating

★★★★★
PRGO's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 20.9%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
PRGO's growth profile is soft, with the least-weak measure being revenue growth at -2.8% FY2025 versus FY2024. By comparison, while earnings growth (-729.7%, negative) and free-cash-flow growth (-40.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 120.0% and approximately 99.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.39%, which materially reduces the ownership score.

Top 5 Institutional Investors

BlackRock Inc 16.36%
Neuberger Berman Group LLC 7.69%
Vanguard Portfolio Management, LLC 6.52%
T. Rowe Price Associates, Inc. 6.27%
State Street Corp 6.14%

Unit Economics (Per $1K Revenue)

★★★★★
PRGO generates approximately $351 of gross profit, $81 of operating income, and $34 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Soft margins explain the 2-star rating, with weak cash conversion and soft capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -8.04% (Tax Credit)

Quantitative Style Profile

★★★★★
PRGO has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Consumer Self-Care AmericasStore-brand OTC medications for retail pharmacies and grocery chains.This is the core engine of the company, providing steady revenue through private-label sales.
Consumer Self-Care InternationalBranded and private-label products across the European and international markets.This segment provides international diversification but faces varying regulatory and competitive landscapes.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-04
When Before Market
Estimate 0.56
Actual 0.6

Profitability

Profit Margin -43.27%
Operating Margin (TTM) 5.53%

Management Effectiveness

Return on Assets (TTM) 1.61%
Return on Equity (TTM) -50.25%

Valuation

Trailing PE -
Forward PE 7.03
Enterprise Value 5.10B
Price to Sales(TTM) 0.55
Enterprise Value 5.10B
Price to Sales(TTM) 0.55
Enterprise Value to Revenue 1.25
Enterprise Value to EBITDA 10.21
Shares Outstanding 138.80M
Shares Floating 138.10M
Shares Outstanding 138.80M
Shares Floating 138.10M
Percent Insiders 0.39
Percent Institutions 119.96

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.